1月27日,康宁杰瑞宣布,其自主研发、与石药集团全资附属公司上海津曼特生物科技有限公司合作开发的安尼妥单抗(KN026)针对HER2阳性胃癌/胃食管结合部腺癌患者的3期临床研究结果,近日成功发表于肿瘤学领域期刊《肿瘤学年鉴》(Annals of Oncology,IF:65.4)。安尼妥单抗注射液是康宁杰瑞采用Fc异二聚体平台技术(CRIB)开发的HER2双特异性抗体,可同时结合HER2的两个非...
Source Link1月27日,康宁杰瑞宣布,其自主研发、与石药集团全资附属公司上海津曼特生物科技有限公司合作开发的安尼妥单抗(KN026)针对HER2阳性胃癌/胃食管结合部腺癌患者的3期临床研究结果,近日成功发表于肿瘤学领域期刊《肿瘤学年鉴》(Annals of Oncology,IF:65.4)。安尼妥单抗注射液是康宁杰瑞采用Fc异二聚体平台技术(CRIB)开发的HER2双特异性抗体,可同时结合HER2的两个非...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.